- Report
- March 2025
- 282 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- October 2024
- 133 Pages
Global
From €2373EUR$2,500USD£2,002GBP
- Report
- July 2024
- 150 Pages
Global
From €3560EUR$3,750USD£3,003GBP
- Report
- March 2023
- 111 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- February 2024
- 110 Pages
Global
From €4509EUR$4,750USD£3,804GBP
- Report
- August 2024
- 123 Pages
China
From €1709EUR$1,800USD£1,441GBP
- Report
- January 2024
- 129 Pages
United States
€3607EUR$3,800USD£3,043GBP
- Report
- August 2023
- 91 Pages
Global
From €3500EUR$3,949USD£3,056GBP
- Report
- August 2024
- 244 Pages
China
From €3797EUR$4,000USD£3,203GBP
Leuprolide is a synthetic hormone used to treat prostate cancer. It is a gonadotropin-releasing hormone (GnRH) agonist, meaning it works by blocking the production of testosterone, which can slow the growth of prostate cancer cells. Leuprolide is typically administered via injection, and is available in both short-acting and long-acting formulations. It is often used in combination with other treatments, such as radiation therapy or chemotherapy.
Leuprolide is a widely used treatment for prostate cancer, and is often prescribed as a first-line therapy. It is generally well-tolerated, with few side effects. Common side effects include hot flashes, fatigue, and nausea.
The leuprolide market is highly competitive, with several major players. These include AbbVie, Astellas Pharma, Endo Pharmaceuticals, and Takeda Pharmaceuticals. Other companies, such as Mylan and Teva Pharmaceuticals, also offer leuprolide products. Show Less Read more